Comparison of Patient Reported Outcomes (Pros) and Clinician Reported Outcomes (Cros) in Patients with Metastatic Brain Disease
Taychakhoonavudh, S.; Franzini, L.; Lal, L.; Chang, E.; Meyers, C.A.; Wefel, J.S.; Swint, J.M.
Value in Health 16(3): A145-A146
2013
ISSN/ISBN: 1098-3015
DOI: 10.1016/j.jval.2013.03.714
Accession: 064295133
PDF emailed within 0-6 h: $19.90
Related References
Chassany, O.; Le-Jeunne, P.; Duracinsky, M.; Schwalm, M-Sophie.; Mathieu, M. 2006: Discrepancies between patient-reported outcomes and clinician-reported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 9(1): 39-46Traina, S.; Li, T.; Johnson, K.; Ho, K.F.; Molina, A.; Cella, D. 2015: Analysis of the Relationship Between Patient-Reported Outcomes (Pros) and Clinical Outcomes In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients without Prior Chemotherapy Value in Health 18(7): A335-A336
Arbuckle, L.; Moher, E.; Bartlett, S.J.; Ahmed, S.; El Emam, K. 2017: Montreal Accord on Patient-Reported Outcomes (PROs) use series - Paper 9: anonymization and ethics considerations for capturing and sharing patient reported outcomes Journal of Clinical Epidemiology 89: 168-172
Bingham, C.O.; Noonan, V.K.; Auger, C.; Feldman, D.E.; Ahmed, S.; Bartlett, S.J. 2017: Montreal Accord on Patient-Reported Outcomes (PROs) use series - Paper 4: patient-reported outcomes can inform clinical decision making in chronic care Journal of Clinical Epidemiology 89: 136-141
Noonan, V.K.; Lyddiatt, A.; Ware, P.; Jaglal, S.B.; Riopelle, R.J.; Bingham, C.O.; Figueiredo, S.; Sawatzky, R.; Santana, M.; Bartlett, S.J.; Ahmed, S. 2017: Montreal Accord on Patient-Reported Outcomes (PROs) use series - Paper 3: patient-reported outcomes can facilitate shared decision-making and guide self-management Journal of Clinical Epidemiology 89: 125-135
Ahmed, S.; Ware, P.; Gardner, W.; Witter, J.; Bingham, C.O.; Kairy, D.; Bartlett, S.J. 2017: Montreal Accord on Patient-Reported Outcomes (PROs) use series - Paper 8: patient-reported outcomes in electronic health records can inform clinical and policy decisions Journal of Clinical Epidemiology 89: 160-167
Mamiya, H.; Lix, L.M.; Gardner, W.; Bartlett, S.J.; Ahmed, S.; Buckeridge, D.L. 2017: Montreal Accord on Patient-Reported Outcomes (PROs) use series - Paper 5: patient-reported outcomes can be linked to epidemiologic measures to monitor populations and inform public health decisions Journal of Clinical Epidemiology 89: 142-147
Fiteni, F.; Cuenant, A.; Favier, M.; Cousin, C.; Houede, N. 2019: Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology In Vivo 33(1): 17-21
Traina, S.; Li, T.; Johnson, K.; Ho, K.F.; Molina, A.; Cella, D. 2015: Is There a Relationship between Patient-Reported Outcomes (Pros) and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Post-Docetaxel? Value in Health 18(7): A470
Bhattacharya, I.S.; Haviland, J.S.; Hopwood, P.; Coles, C.E.; Yarnold, J.R.; Bliss, J.M.; Kirby, A.M. 2019: Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 134: 220-230
Seal, B.S.; Asche, C.V.; Puto, K.; Allen, P.D. 2013: Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 16(5): 872-890
Jokstad, Aørn. 2018: Patient-reported outcomes (PROs) versus patient-reported outcome measures (PROMs)-Is there a difference? Clinical and Experimental Dental Research 4(3): 61-62
Freeman, M.; Gupte-Singh, K.; You, M.; Le, T.K.; Ritchings, C.; Rao, S.; Jang, S. 2018: Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort study Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii457
Wang, H.; Wu, D.; Cai, L.; Li, X.; Zhang, Z.; Chen, S. 2020: Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer Journal of cellular and molecular medicine 24(12): 6869-6882
Basch, E.; Bennett, A.; Pietanza, M.Catherine. 2011: Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events Journal of the National Cancer Institute 103(24): 1808-1810